Related Experiment Video
Updated: Jan 9, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.3K
Consultation-Liaison Case Conference: Stimulant-Induced Tardive Dyskinesia
Mansoor Malik1, Trung Tran1, Partam Manalai2
1Johns Hopkins University, Baltimore, MD.
Journal of the Academy of Consultation-Liaison Psychiatry
|December 5, 2025
Summary
Stimulant medications can cause tardive dyskinesia, a movement disorder, in patients with attention deficit hyperactivity disorder. Discontinuing stimulants and switching to medications like quetiapine can significantly improve symptoms.
Area of Science:
- Psychiatry
- Neurology
- Pharmacology
Background:
- Tardive dyskinesia (TD) is a serious side effect of certain medications.
- Stimulant medications are commonly used for attention deficit hyperactivity disorder (ADHD).
- Managing TD in patients with complex psychiatric histories and polypharmacy presents challenges.
Purpose of the Study:
- To present a case of tardive dyskinesia (TD) in a patient with attention deficit hyperactivity disorder (ADHD) and complex psychiatric conditions.
- To highlight the role of stimulants in exacerbating movement disorders.
- To review treatment strategies for TD.
Main Methods:
- Case presentation of a 35-year-old nonbinary patient.
- Review of literature on stimulant-induced movement disorders and TD treatment.
- Analysis of treatment outcomes following medication adjustments.
Main Results:
- The patient developed TD after initiating amphetamine/dextroamphetamine.
- Discontinuing the stimulant and switching to quetiapine led to significant improvement in TD.
- Stimulants are associated with tics, dyskinesia, and TD, especially in ADHD populations.
Conclusions:
- Stimulant-induced movement disorders, including TD, require vigilant monitoring in patients with ADHD.
- Treatment strategies for TD include discontinuing offending agents, switching antipsychotics, and considering Vesicular monoamine transporter 2 inhibitors.
- Individualized treatment approaches are crucial for managing TD in high-risk patients.
Related Concept Videos
01:24Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
01:28Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
01:23Drugs Acting on Autonomic Ganglia: Stimulants
2.0K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.0K
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:16Therapeutic Drug Monitoring: Overview and Classification
275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275